Records containing: Obesity
This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.
Follow recorded terms in Drug Alerts for Android. Free includes unlimited local condition follows and an on-open recent-record watchlist. Plus adds no ads and personal organization tools.
All
FDA submission records
EMA medicine records
ClinicalTrials.gov record updates
ClinicalTrials.gov records with results posted
-
CLINICAL_TRIALS study record update · 2026-10-30Vitamin E Pharmacokinetics and Biomarkers in Normal and Obese Women
-
CLINICAL_TRIALS study record update · 2026-10-30A Phase 1/2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARO-INHBE in Adult Volunteers With Obesity With and Without Diabetes Mellitus
-
CLINICAL_TRIALS study record update · 2026-10-30Evaluation of the Clinical Spectrum of Diabetes and Obesity in Youth and Adults
-
CLINICAL_TRIALS study record update · 2026-10-29A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Maridebart Cafraglutide on Mortality and Morbidity in Participants Living With Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (MARITIME-HF)
-
CLINICAL_TRIALS study record update · 2026-10-29Diabetes and Heart Disease Risk in Blacks
- Organize your saved records without ads with Plus.
-
CLINICAL_TRIALS study record update · 2026-10-29Inhibition of Intestinal Glucose Absorption by the Bioflavonoid Quercetin in the Obese and in Obese Type 2 Diabetics
-
CLINICAL_TRIALS study record update · 2026-10-29Fighting Western-diet Derived AGEs to Mitigate Muscle Wasting in Sarcobesity:Observational Study on the Relationship Between AGE Levels and Sarcobesity in an Adult Population Affected by Obesity and Type 2 Diabetes Mellitus
-
CLINICAL_TRIALS study record update · 2026-10-29Molecular and Clinical Profile of Diabetes Mellitus and Its Complications
-
CLINICAL_TRIALS study record update · 2026-10-29Identifying Risk for Diabetes and Heart Disease in Women: A Study of African-American, African and White Federal Employees and Contractors
-
CLINICAL_TRIALS study record update · 2026-10-29Cross-Sectional and Longitudinal Studies of 'Pre-Diabetes'
-
CLINICAL_TRIALS study record update · 2026-10-28Gestational Weight Loss and Restrictive Weight Gain Across Maternal Obesity Classes: A Nationwide Target Trial Emulation in the United States
-
CLINICAL_TRIALS study record update · 2026-10-28A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Once-Weekly Eloralintide in Adult Participants With Obesity or Overweight, Type 2 Diabetes, and Increased CV Risk
-
CLINICAL_TRIALS study record update · 2026-10-28Prevention of Diabetes With a Novel Butyrate-enriched Triglyceride
-
CLINICAL_TRIALS study record update · 2026-10-14HealthMatters@24/7 Asynchronous Health Promotion eLearning for People Supporting Adults With Intellectual and Developmental Disabilities
-
CLINICAL_TRIALS study record update · 2026-10-07Long-term Safety and Efficacy of Semaglutide s.c. Once-weekly on Weight Management in Children and Adolescents (Aged 6 to <18 Years) With Obesity or Overweight
-
CLINICAL_TRIALS study record update · 2026-10-01PANCREATIC NUTRITIONAL PROGRAM (PNP): A Novel Weight Reduction Program in Overweight/Obese Breast Cancer Survivors
-
CLINICAL_TRIALS study record update · 2026-09-30Efficacy and Safety of Cagrilintide s.c. 2.4 Milligram (mg) in Combination With Semaglutide Subcutaneous (s.c). 2.4 mg (CagriSema s.c. 2.4 mg/2.4 mg) Once-weekly in Participants With Overweight or Obesity
-
CLINICAL_TRIALS study record update · 2026-09-17A Phase 3, Randomised, Double-blind, Parallel-group, Event-driven, Cardiovascular Safety Study With BI 456906 Administered Subcutaneously Compared With Placebo in Participants With Overweight or Obesity With Established Cardiovascular Disease (CVD) or Chronic Kidney Disease, and/or at Least Two Weight-related Complications or Risk Factors for CVD
-
CLINICAL_TRIALS study record update · 2026-09-09Long-term Safety and Efficacy of Semaglutide s.c. Once-weekly on Weight Management in Children and Adolescents (Aged 6 to <18 Years) With Obesity or Overweight
-
CLINICAL_TRIALS study record update · 2026-09-03A Phase 3, Randomised, Double-blind, Parallel-group, Event-driven, Cardiovascular Safety Study With BI 456906 Administered Subcutaneously Compared With Placebo in Participants With Overweight or Obesity With Established Cardiovascular Disease (CVD) or Chronic Kidney Disease, and/or at Least Two Weight-related Complications or Risk Factors for CVD
-
CLINICAL_TRIALS study record update · 2026-08-31Efficacy and Safety of Cagrilintide s.c. 2.4 Milligram (mg) in Combination With Semaglutide Subcutaneous (s.c). 2.4 mg (CagriSema s.c. 2.4 mg/2.4 mg) Once-weekly in Participants With Overweight or Obesity
-
CLINICAL_TRIALS study record update · 2026-08-11A Phase 3, Randomised, Double-blind, Parallel-group, Event-driven, Cardiovascular Safety Study With BI 456906 Administered Subcutaneously Compared With Placebo in Participants With Overweight or Obesity With Established Cardiovascular Disease (CVD) or Chronic Kidney Disease, and/or at Least Two Weight-related Complications or Risk Factors for CVD
-
CLINICAL_TRIALS study record update · 2026-08-06A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial: Multiple Independent Sub-studies of Setmelanotide in Patients With POMC/PCSK1, LEPR, NCOA1(SRC1), or SH2B1 Gene Variants in the Melanocortin-4 Receptor Pathway
-
CLINICAL_TRIALS study record update · 2026-07-30A Master Protocol to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight: A Randomized Double-Blind, Placebo-Controlled Trial
-
CLINICAL_TRIALS study record update · 2026-07-30A Randomized, Double-Blind, Phase 3 Study to Investigate the Efficacy and Safety of LY3437943 Once Weekly Compared to Placebo in Participants With Severe Obesity and Established Cardiovascular Disease